Hey KZ, the depth of your research or lack thereof is amazing. Firstly, how could they trade at 5c as you earlier claim when they have $83million in assets, which almost supports the current SP alone. You say Nexavar is much better, well you must have an insight into PGLs phase 3 trial nobody else has. What I do know is that there is not so much to beat with Nexavar overall survival at 10.7 months against placebo 7.9 months. Then there are PGLs phase 2's in Prostate and others to add value. Largest PGL shareholder in the USA is SAC Capital, so I guess Steve Cohn does not agree with your prediction. Latest short numbers about 16000. Would any of that be you??? This is looking like a buy. Do your own research, I have only done a quick search and could be wrong.
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
